Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis

PHASE1TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 2, 2015

Primary Completion Date

March 15, 2017

Study Completion Date

March 15, 2017

Conditions
Severe SepsisSeptic Shock
Interventions
BIOLOGICAL

BMS-936559

OTHER

Placebo

Trial Locations (13)

30322

Emory University, Atlanta

32610

University Of Florida, Gainesville

43210

The Ohio State University, Columbus

43603

St. Vincent'S Medical Center, Toledo

61637

Osf Saint Francis Medical Center, Peoria

63110

Washington University School Of Medicine, St Louis

80204

Local Institution, Denver

95817

Uc Davis Medical Center, Sacramento

98104

Local Institution, Seattle

02114

Massachusetts General Hospital, Boston

01199

Baystate Medical Center, Springfield

48109-5033

University of Michigan, Division of Acute Care Surgery, Ann Arbor

15261-2500

UPMC, Pittsburgh

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02576457 - Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis | Biotech Hunter | Biotech Hunter